MannKind Corporation
MNKDMannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
Drugs in Pipeline
15
Phase 3 Programs
9
Upcoming Catalysts
3
Next Catalyst
Sep 22, 2026
32wMarket Overview
Stock performance and market intelligence
3 upcoming, 0 past
FDA PDUFA Date MannKind's product (standard)
For diabetes. NDA filing. Extracted from SEC filing: 8-K
SourceTechnosphere Insulin Phase 2 Results Expected
Primary completion for Technosphere Insulin trial (NCT07224321) in Type 1 Diabetes Mellitus
SourceBasal insulin Phase 2 Results Expected
Primary completion for Basal insulin trial (NCT07224321) in Type 1 Diabetes Mellitus
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Metformin & Secretagogues
Diabetes Mellitus, Type 2
Technosphere® Insulin with MedTone C Inhaler
Type 1 Diabetes Mellitus
Usual Care
Diabetes, Type 1
Technosphere® Insulin
Type 2 Diabetes
Technosphere® Insulin Inhalation Powder
Diabetes Mellitus: Type 1
70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Diabetes Type 2
Active comparator
Diabetes, Type I
Technosphere Insulin
Type 2 Diabetes Mellitus
Afrezza
Diabetes Mellitus, Type 1
Basal insulin
Type 1 Diabetes Mellitus
Technosphere/Insulin
Diabetes Mellitus, Type 2
Actrapid
Type 2 Diabetes Mellitus
MKC1106-MT
Melanoma (Skin)
Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Type 2 Diabetes Mellitus
Technosphere Insulin Inhalation Powder
Diabetes Type 2
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Metformin & Secretagogues | Phase 3 | Diabetes Mellitus, Type 2 | - |
Technosphere® Insulin with MedTone C Inhaler | Phase 3 | Type 1 Diabetes Mellitus | - |
Usual Care | Phase 3 | Diabetes, Type 1 | - |
Technosphere® Insulin | Phase 3 | Type 2 Diabetes | - |
Technosphere® Insulin Inhalation Powder | Phase 3 | Diabetes Mellitus: Type 1 | - |
70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) | Phase 3 | Diabetes Type 2 | - |
Active comparator | Phase 3 | Diabetes, Type I | - |
Technosphere Insulin | Phase 3 | Type 2 Diabetes Mellitus | - |
Afrezza | Phase 3 | Diabetes Mellitus, Type 1 | - |
Basal insulin | Phase 2 | Type 1 Diabetes Mellitus | - |
Technosphere/Insulin | Phase 2 | Diabetes Mellitus, Type 2 | - |
Actrapid | Phase 2 | Type 2 Diabetes Mellitus | - |
MKC1106-MT | Phase 2 | Melanoma (Skin) | - |
Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler | Phase 2 | Type 2 Diabetes Mellitus | - |
Technosphere Insulin Inhalation Powder | Phase 2 | Diabetes Type 2 | - |
Regulatory & News
Approvals, filings, and latest developments